TheraRadar
Data updated: May 26, 2026

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE (sitagliptin, metformin hydrochloride)

Metabolic Approved 2025-06-04
3
Indications
--
Phase 3 Trials
0
Years on Market

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE Approval History

2026
Original
New Indication
New Form
Label Update
7 FDA actions from 2025 to 2026
Apr 2026 ORIGINAL
Update
Dec 2025 ORIGINAL
Update
Jun 2025 ORIGINAL
Update

What SITAGLIPTIN AND METFORMIN HYDROCHLORIDE Treats

3 FDA approvals

Originally approved for its first indication in 2025 . Covers 3 distinct patient populations.

  • Other (3)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

SITAGLIPTIN AND METFORMIN HYDROCHLORIDE FDA Label Details

Track SITAGLIPTIN AND METFORMIN HYDROCHLORIDE with TheraRadar Pro

Watchlist alerts, full database access, CSV exports across 14,000+ drugs.

Upgrade to Pro

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.